Description of the invention will be available after the patent application is published.
Description of the invention will be available after the patent application is published.
Description of the invention will be available after the patent application is published.
Patent was granted in Poland and Nencki Institute is the sole applicant.
The subject of the present invention is a method for detecting active, remyelinating lesions in patients diagnosed with multiple sclerosis through the determination of changes in the levels of interleukin-33 in peripheral blood and cerebrospinal fluid, which constitutes a novel marker of endogenous repair processes facilitating the monitoring of the differentiation of oligodendrocyte precursor differentiation…
The present invention relates to methods for the identification of single nucleotide polymorphisms (SNP) in the GRHL1, GRHL2 and GRHL3 genes and the use of these polymorphisms as markers to identify patients at increased susceptibility to cancer of the kidneys.
The invention relates to the diagnosis of the pre-diabetoc state and processes underlying development of diabetic state way before blood glucose levels are abnormaln and diabetes clinical symptoms occur. This may be done using the relative proportion of the level of the Wnt4 and Wnt3a proteins in blood plasma. wew ew Briefly, in prediabetic state…
A device (1) for immobilizing an animal in order to examine a selected area of the animal’s body, the device (1) comprising two upright members (2a, 2b) secured by their lower ends to a base (3), the height of the upright members (2a, 2b) being adjustable independently of one another and being adapted to be…
This invention relates generally to the field of cancer diagnostics, and in particular to the detection of an increased risk of developing a skin cancer. Specifically, the present invention relates to a method of detecting and identifying an increased risk of developing a skin cancer in a human patient based on polymorphisms of the GRHL3…
The present invention relates to a genetically encoded FRET-based biosensor to monitor the activity of matrix metalloproteinase 9 (MMP-9). MMP-9 is an extracellular acting endopeptidase implicated in both physiological and pathological processes. A genetically encoded FRET biosensor anchored in the cellular membrane allows studying the proteolytic activity of MMP-9 with high spatiotemporal resolution at the…